Share on StockTwits

Aegerion Pharmaceuticals (NASDAQ:AEGR) CFO Mark J. Fitzpatrick purchased 1,150 shares of Aegerion Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average cost of $30.64 per share, with a total value of $35,236.00. Following the acquisition, the chief financial officer now directly owns 9,500 shares in the company, valued at approximately $291,080. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

AEGR has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note on Friday, August 15th. They now have a $58.00 price target on the stock, down previously from $70.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Aegerion Pharmaceuticals in a research note on Wednesday, July 16th. They now have a $29.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $61.75.

Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded up 1.60% on Wednesday, hitting $31.21. 146,470 shares of the company’s stock traded hands. Aegerion Pharmaceuticals has a one year low of $26.25 and a one year high of $101.00. The stock has a 50-day moving average of $30.34 and a 200-day moving average of $40.97. The company’s market cap is $920.5 million.

Aegerion Pharmaceuticals (NASDAQ:AEGR) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.08. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $35.40 million. During the same quarter in the prior year, the company posted ($0.66) earnings per share. The company’s quarterly revenue was up 453.8% on a year-over-year basis. Analysts expect that Aegerion Pharmaceuticals will post $-0.86 EPS for the current fiscal year.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.